The Scientist

» BioTime

Most Recent

image: Geron hESC Trial to Resume?

Geron hESC Trial to Resume?

By | May 27, 2014

Nearly three years after Geron shuttered its stem cell program, BioTime receives funding to relaunch a Phase 1 trial for spinal cord injury.

0 Comments

image: Geron Sells Stem Cell Assets

Geron Sells Stem Cell Assets

By | January 8, 2013

BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.

0 Comments

Popular Now

  1. Major German Universities Cancel Elsevier Contracts
  2. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  3. Most of Human Genome Nonfunctional: Study
  4. Identifying Predatory Publishers
AAAS